tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

XtalPi and DoveTree Enter Definitive Agreement for AI-Driven Drug Discovery

Story Highlights

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

QuantumPharm, Inc. ( (HK:2228) ) has shared an announcement.

XtalPi Holdings Limited, through its subsidiary Shenzhen XtalPi Technology Co., Ltd., has entered into a definitive agreement with DoveTree Medicines LLC to leverage its AI drug discovery platform for developing small molecule and antibody drug candidates. This collaboration focuses on oncology, immunologic and inflammatory diseases, neurological disorders, and metabolic dysregulation, with DoveTree obtaining exclusive development and commercialization rights. The agreement includes an initial payment of $51 million to XtalPi, with potential further payments and royalties based on product sales.

The most recent analyst rating on (HK:2228) stock is a Buy with a HK$7.57 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.

More about QuantumPharm, Inc.

Average Trading Volume: 99,746,828

Technical Sentiment Signal: Sell

Current Market Cap: HK$22.89B

For a thorough assessment of 2228 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1